Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Background Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. Initial...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-09-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/9/e003149.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
by: Chenyun Zhang, et al.
Published: (2025-01-01)

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01)

Preclinical model for evaluating human TCRs against chimeric syngeneic tumors
by: Olivier Michielin, et al.
Published: (2024-12-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
by: Yelei Guo, et al.
Published: (2016-01-01)

Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia
by: Haotian Ma, et al.
Published: (2024-11-01)

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01)

Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood
by: Ji U Choi, et al.
Published: (2025-01-01)

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
by: Caitlin R Hopkins, et al.
Published: (2021-12-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

The Efficacy of Chimeric Antigen Therapy in Viral Infectious Diseases: A Systematic Review of Randomized Controlled Trials
by: Hossein Hatami, et al.
Published: (2024-12-01)

Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: A systematic review.
by: Karine Ferreira Lopes, et al.
Published: (2024-12-01)

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01)

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
by: Amneet Bajwa, et al.
Published: (2025-01-01)

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
by: Jinlan Long, et al.
Published: (2025-01-01)

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
by: Yan-Ruide Li, et al.
Published: (2025-02-01)

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
by: Marie José Kersten, et al.
Published: (2025-01-01)

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)

Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation
by: John S. Wang, et al.
Published: (2022-01-01)

Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen
by: Eleni Gourni PhD, et al.
Published: (2017-10-01)

Minor Antigen Disparities Impede Induction of Long Lasting Chimerism and Tolerance through Bone Marrow Transplantation with Costimulation Blockade
by: Sinda Bigenzahn, et al.
Published: (2016-01-01)

Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
by: Ruihao Huang, et al.
Published: (2025-01-01)

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
by: Shatha Farhan, et al.
Published: (2017-01-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies
by: Max Topp, et al.
Published: (2024-12-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Effects of different vaccination regimes on the immunodiagnosis of tuberculosis in goats and evaluation of defined antigens
by: Patricia Cuenca-Lara, et al.
Published: (2025-01-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
by: Xin Liu, et al.
Published: (2022-03-01)

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
by: Hongyan Liu, et al.
Published: (2023-01-01)

Néotène, Hybrides et Chimères
by: Marika Moisseeff
Published: (2019-07-01)

Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity.
by: Mostafa Omidian, et al.
Published: (2024-07-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Correction: Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity.
by: Mostafa Omidian, et al.
Published: (2025-01-01)

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”
by: Vanessa Fairhurst, et al.
Published: (2025-01-01)

An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
by: Bin Xue, et al.
Published: (2025-01-01)

Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15
by: Xin Xu, et al.
Published: (2025-01-01)